ArticleAdvances in therapy2019

Efficacy and Safety of 8 Weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve, HCV-Infected Patients with APRI ≤ 1 in a Single-Arm, Open-Label, Multicenter Study.

Robert J Fontana et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.